Suchergebnisse - "Uchino, Junji"

PubPharm (107)

1

A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy : The SPIRAL-RT study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Yamada, T. | Goto, Y. | Tanaka, H. | +9

2

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study)

enthalten in: Translational lung cancer research | 2023

von Sawada, R. | Nishioka, N. | Kim, Y. | +3

3

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer : A multicenter, Phase II trial

enthalten in: Cancer medicine | 2023

von Iwasaku, M. | Uchino, J. | Chibana, K. | +16

4

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases : A Multicenter, Open-Label Single-Arm Phase II Trial

enthalten in: The oncologist | 2023

von Tanimura, K. | Uchino, J. | Kimura, H. | +11

5

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations

enthalten in: Proteomes | 2023

von Noguchi, R. | Yoshimura, A. | Uchino, J. | +7

6

Changes in blood pressure and arterial stiffness monitored using the cardio-ankle vascular index during hemodialysis

enthalten in: Frontiers in physiology | 2023

von Sato, S. | Shimizu, K. | Takahashi, M. | +7

7

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II) : A Single-Arm, Open-Label, Phase 2 Clinical Trial

enthalten in: JTO clinical and research reports | 2022

von Hibino, M. | Hiranuma, O. | Takemura, Y. | +17

8

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

enthalten in: Journal of cancer research and clinical oncology | 2022

von Nakamura, R. | Yamada, T. | Morimoto, K. | +17

9

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients : The SPIRAL-0 Study

enthalten in: The oncologist | 2022

von Chihara, Y. | Takeda, T. | Goto, Y. | +20

ErratumIn: Oncologist. 2024 Mar 18;:. - PMID 38498842

10

Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer : a retrospective study

enthalten in: Journal of cancer research and clinical oncology | 2022

von Morimoto, K. | Uchino, J. | Yokoi, T. | +16

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]